- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BriaCell Announces Proposed Investment by Leading Biotech Funds
BriaCell Therapeutics (TSXV:BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it expects to enter into a securities purchase agreement of convertible notes with a leading group of Institutional and Family Office funds focused on investments in the biotech sector for an investment of US$800,000. As quoted in the …
BriaCell Therapeutics (TSXV:BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it expects to enter into a securities purchase agreement of convertible notes with a leading group of Institutional and Family Office funds focused on investments in the biotech sector for an investment of US$800,000.
As quoted in the press release:
Concurrent with the Note Offering, the Company also announced today that it intends complete a non-brokered private placement (the “Non-Brokered Unit Offering”) of units of the Company (the “Units”) at a price of $0.10 per Unit for aggregate gross proceeds of up to C$4,000,000. The Non-Brokered Unit Offering is in addition to BriaCell’s proposed strategic US$800,000 Note Offering and also includes an investment from a recognized Biotech Family office in the United States. Under the Non-Brokered Unit Offering, each Unit shall consist of one Common Share and one Warrant. The Warrants will be valid for 36 months following the date of closing of the Non-Brokered Unit Offering and each Warrant will be exercisable for one Common Share at an exercise price of C$0.14.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â